NEW YORK (GenomeWeb News) – Vermillion expects to raise $43 million in gross proceeds from a private placement of around 2.3 million shares with a group of unnamed investors.

The Fremont, Calif.-based molecular diagnostics firm is currently operating under Chapter 11 bankruptcy protection. It said that the private placement is subject to approval of Vermillion's reorganization plan by the US Bankruptcy Court in Delaware, and would take effect on or about Jan. 7, 2010, when a hearing on the reorganization plan is scheduled.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.